Tag: CLDN18.2

Elevation Oncology, an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, said it will prioritize key research and development efforts to advance EO-3021 (SYSA1801), its potential best-in-class antibody-drug conjugate (ADC) designed to target Claudin 18.2, and other pipeline programs including those through its existing partnership with Caris Life Sciences.

Chinese WuXi XDC, a joint venture between WuXi Biologics and WuXi STA, a Contract Research, Development and Manufacturing Organization focusing on end-to-end bioconjugates services, and...